Publisher
Springer International Publishing
Reference10 articles.
1. Balarini Lima GA, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary. 2008;11(3):287–92.
2. dos Santos NV, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14(3):259–65.
3. Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, Degli Uberti E, Zatelli MC. Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary. 2013;16(1):91–100.
4. Lundin P, Bergström K, Nyman R, Lundberg PO, Muhr C. Macroprolactinomas: serial MR imaging in long-term bromocriptine therapy. AJNR Am J Neuroradiol. 1992;13(5):1279–91.
5. Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary. 2011;14(1):68–74.